|
gptkbp:instanceOf
|
vaccine
|
|
gptkbp:administeredBy
|
intramuscular injection
|
|
gptkbp:alsoKnownAs
|
gptkb:Oxford–AstraZeneca_COVID-19_vaccine
gptkb:AZD1222
gptkb:Covishield
|
|
gptkbp:antigen
|
gptkb:SARS-CoV-2_spike_protein
|
|
gptkbp:approvedBy
|
gptkb:Australia
gptkb:Brazil
gptkb:Canada
gptkb:European_Union
gptkb:India
gptkb:United_Kingdom
gptkb:World_Health_Organization
December 2020
|
|
gptkbp:category
|
gptkb:COVID-19_vaccines
gptkb:COVID-19_pandemic_in_the_United_Kingdom
|
|
gptkbp:clinicalTrialPhase
|
Phase III
|
|
gptkbp:contraindication
|
severe allergic reaction to previous dose
|
|
gptkbp:countryOfOrigin
|
gptkb:United_Kingdom
|
|
gptkbp:developedBy
|
gptkb:University_of_Oxford
gptkb:AstraZeneca
|
|
gptkbp:dosesRequired
|
2
|
|
gptkbp:effect
|
about 70%
|
|
gptkbp:emergencyServices
|
gptkb:World_Health_Organization
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
ChAdOx1 nCoV-19 vaccine
|
|
gptkbp:includedIn
|
gptkb:COVAX
|
|
gptkbp:notRecommendedFor
|
children under 18 (initially)
people with history of thrombosis with thrombocytopenia syndrome
|
|
gptkbp:patent
|
gptkb:University_of_Oxford
gptkb:AstraZeneca
|
|
gptkbp:producedBy
|
gptkb:SK_Bioscience
gptkb:Serum_Institute_of_India
gptkb:Fiocruz
|
|
gptkbp:regulates
|
gptkb:WHO
gptkb:EMA
gptkb:MHRA
gptkb:DCGI
|
|
gptkbp:sideEffect
|
fever
fatigue
headache
muscle pain
rare blood clots
|
|
gptkbp:storage
|
2–8°C
|
|
gptkbp:target
|
gptkb:COVID-19
|
|
gptkbp:technology
|
recombinant DNA
|
|
gptkbp:type
|
viral vector vaccine
|
|
gptkbp:usedIn
|
mass vaccination campaigns
|
|
gptkbp:vectorFor
|
gptkb:chimpanzee_adenovirus
|
|
gptkbp:WHOEmergencyUseListing
|
February 2021
|
|
gptkbp:bfsParent
|
gptkb:Vaccitech
gptkb:chimpanzee_adenovirus_(ChAdOx1)
|
|
gptkbp:bfsLayer
|
7
|